![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/spacer.gif)
yttrium Y 90-DOTA-chimeric monoclonal antibody cG250 A radioimmunoconjugate comprised of the chimeric monoclonal antibody cG250 conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and lableled with the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90 DOTA chimeric monoclonal antibody cG250 binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/spacer.gif)
Abbreviation: | ![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/spacer.gif) | 90Y-DOTA-cG250 | | ![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081025105104im_/http://www.cancer.gov/images/spacer.gif) |